1. Call topic identification for 2019 call
Laura Plant
JPIAMR Secretariat
26th February 2018

2. JPIAMR Calls to date…
2014 Therapeutics: InnovaResistance: Innovative approaches to address antibacterial resistance
2015 Therapeutics: Antimicrobial Resistance through the JPIAMR
2016 Transmission: Transmission Dynamics
2017 Intervention : Comparison of prevention, control and intervention strategies for AMR infections through multidisciplinary studies, including One Health approaches
2018 Therapeutics: Innovations against antibiotic-resistant bacteria: new targets, compounds and tools. Fundamental, translational research, with the exception of clinical trials

3. 2019 Call topic process Survey open from Dec 2017 to Jan 2018.
Twelve ares surveyed, asking the following questions:
Topic has a high impact on reducing the burden of AMR?
Topic has a high impact on translation of research into clinical practice, commercialisation of output, and policy uptake?
Topic enables larger scale projects that use data and infrastructure not available within a single country (avoids fragmentation and duplication)?
Topic will create new networks including researchers from countries not represented adequately up to now?
Topic enhances capacity building in countries not represented adequately up to now?
Topic strengthens the European or other regional research areas?
Questions 1 and 2 surveyed the importance of the topic to the issue of AMR, while questions 3-6 addressed the benefit of running the call as a joint transnational call. Both aspects were weighted equally in the analysis of the results of the survey.

4. Survey Topic 2019: DIAGNOSTICS
Identification of appropriate diagnostic markers or development and validation of new better diagnostic tools and methods for discrimination between viral and bacterial infections, detecting and identifying antibiotic resistant bacteria, and/or monitoring the clinically relevant load of resistant pathogens. Tests should be rapid, reliable, and affordable and developed for specific pathologies to be implemented bedside/point of care for antimicrobial susceptibility testing in order to promote the use of narrow spectrum antibiotics.

5. DIAGNOSTICS Other diagnostic calls
IMI : AMR priority: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use.
ZonMw Antibiotic Resistance: 1. Mechanisms of acquiring and transmitting antibacterial resistance in different environment such as patients, farms and nature; 2. Appropriate use of diagnostics; 3. Optimising antibiotic dosage and prudent use.

6. SURVEILLANCE (rank 2 and 3)
Alternative Topics 2019
SURVEILLANCE (rank 2 and 3)
To design and perform longitudinal or modelling studies of AMR/ATB use and/or to perform a pilot study on the feasibility of a global phenotypic and genotypic surveillance program
Other surveillance calls
JPIAMR 2018 Surveillance Network Call
WHO GLASS surveillance programme (aiming standardised protocols)
Fleming fund
Surveillance
ECDC and National Agencies

7. INTERVENTION, TRANSMISSION & ENVIRONMENT
Alternative Topics 2019
INTERVENTION, TRANSMISSION & ENVIRONMENT
(rank 4, 5 & 6)
To evaluate strategies for (behavioural) interventions to limit the transmission of bacterial and genetic elements conferring antimicrobial resistance (AMR) at the societal and environmental level, in order to improve monitoring and risk assessment, or design and evaluate preventive and intervention measures for controlling resistance.
Other intervention, transmission & environment calls
JPIAMR 2018 sixth joint call focus is – new targets, compounds and tools
Environmental Protection Agency Ireland: Assessment of the relative contribution of various sectors to the impact and persistence of antimicrobial resistance in the environment and development of sector-specific solutions to halt further spread.

8. DECISION Option A: Diagnostics Option B: Surveillance
Identification of appropriate diagnostic markers or development and validation of new better diagnostic tools and methods for discrimination between viral and bacterial infections, detecting and identifying antibiotic resistant bacteria, and/or monitoring the clinically relevant load of resistant pathogens. Tests should be rapid, reliable, and affordable and developed for specific pathologies to be implemented bedside/point of care for antimicrobial susceptibility testing in order to promote the use of narrow spectrum antibiotics.
Option B: Surveillance
To design and perform longitudinal or modelling studies of AMR/ATB use and/or to perform a pilot study on the feasibility of a global phenotypic and genotypic surveillance program
Option C: Combined Intervention, Transmission, Environment
To evaluate strategies for (behavioural) interventions to limit the transmission of bacterial and genetic elements conferring antimicrobial resistance (AMR) at the societal and environmental level, in order to improve monitoring and risk assessment, or design and evaluate preventive and intervention measures for controlling resistance.